Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

detoxification · Mechanism Report

Can urinary mycotoxin tests identify an indoor mold source?

Urinary aflatoxin and fumonisin markers indicate recent exposure but cannot identify indoor mold as the source.

PlausibleNovember 21, 202610 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Detection of urinary aflatoxin metabolites or fumonisin biomarkers indicates recent exposure to these food- or environment-derived mycotoxins but does not, by itself, identify an indoor mold source.

laying out figure…
0 of 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

Aflatoxin metabolites and fumonisin in urine reflect short-term exposure, which can occur through contaminated food. These markers do not distinguish exposure routes or establish illness or a harmful dose.

Verified conclusion

Urinary aflatoxin and fumonisin testing can document internal exposure over a short time window, but it cannot determine whether an indoor environment was the source.

Clinical interpretation

  • Aflatoxin: Urinary aflatoxin M₁ (AFM₁) and aflatoxin-N7-guanine are validated markers of recent exposure, generally reflecting the preceding 1–3 days; AFM₁ commonly reflects the prior 24–48 hours.
  • Fumonisin: Urinary fumonisin B₁ (FB₁) is also a short-term exposure marker. In controlled maize-consumption research, urinary FB₁ rose during consumption and became undetectable within 5 days after intake stopped.
  • A positive result does not diagnose mycotoxin-related illness, establish a harmful dose, or reliably estimate individual intake. AFM₁ represents only about 1–3% of ingested aflatoxin B₁ excretion, while urinary FB₁ recovery is <1% and highly variable. Spot samples are additionally affected by timing and urine dilution.

Mechanistic and source considerations

  • AFM₁ is produced through metabolism of aflatoxin B₁ and then excreted in urine; dietary intake is a well-supported contributor to urinary AFM₁.
  • Dietary fumonisin intake similarly produces urinary FB₁, although the intake–urine relationship is modest and variable.
  • Neither marker differentiates ingestion from inhalation or another exposure route. Because these mycotoxins are established food contaminants, food exposure is an important alternative explanation for detectable urinary levels.

Clinical implications

  • Clinical guidance does not support using urine mycotoxin results alone to diagnose illness due to indoor mold or to identify a particular building as the exposure source. No validated threshold, source-attribution algorithm, or diagnostic-accuracy framework establishes such a link.

Bottom line

  • The claim is well supported: urinary aflatoxin metabolites and FB₁ indicate recent exposure, but a positive test alone cannot identify indoor mold as the source or establish toxicity, symptoms, or clinical risk.

References

  1. Development and Limitations of Exposure Biomarkers to Dietary ... — ncbi.nlm.nih.gov ↗
  2. Human biomonitoring of mycotoxins: key challenges ... - Springer — link.springer.com ↗
  3. Human biomonitoring of mycotoxins: key challenges and future directions - Mycotoxin Research — link.springer.com ↗
  4. The Kinetics of Urinary Fumonisin B1 Excretion in Humans Consuming Maize-Based Diets — pmc.ncbi.nlm.nih.gov ↗
  5. ACMT Position Statement: Medical Toxicology Considerations in ... — acmt.net ↗
  6. Mycotoxin quantification in fungal/mold allergy — aaaai.org ↗
  7. Abridged version of the AWMF guideline for the medical ... — link.springer.com ↗
  8. Mycotoxins—Biomonitoring and Human Exposure — ncbi.nlm.nih.gov ↗
  9. CHAPTER 1. Human exposure to aflatoxins and fumonisins — ncbi.nlm.nih.gov ↗
  10. Development and Limitations of Exposure Biomarkers to ... — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible9 sourcesCan urine testing detect a mixed burden of mycotoxins, BPA, PFAS, and metals?→Plausible4 sourcesCan reduced glutathione capacity increase susceptibility to toxicant-related oxidative injury?→